Riluzole in the treatment of mood and anxiety disorders. - Wikidata - wikimedia - TriplyDB

Riluzole in the treatment of mood and anxiety disorders.

Riluzole in the treatment of mood and anxiety disorders.

http://www.wikidata.org/entity/Q37242602

about

Obsessive-compulsive disorder and related disorders: a comprehensive survey Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral Sclerosis A New Outlook on Mental Illnesses: Glial Involvement Beyond the Glue Pharmacological treatment of anxiety disorders: current treatments and future directions Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?Chemical-genetic screen identifies riluzole as an enhancer of Wnt/β-catenin signaling in melanoma Psychotherapy and medication management strategies for obsessive-compulsive disorder.Efficacy of Glutamate Modulators in Tic Suppression: A Double-Blind, Randomized Control Trial of D-serine and Riluzole in Tourette Syndrome Glutamate modulators in the treatment of obsessive-compulsive disorder.Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.Glutamatergic agents for OCD and related disorders Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD.Riluzole effect on occipital cortex: a structural and spectroscopy pilot study.Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression Action control is mediated by prefrontal BDNF and glucocorticoid receptor binding Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice.From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide--a 3T-MRS study in healthy subjects Neurotransmitter signaling pathways required for normal development in Xenopus laevis embryos: a pharmacological survey screen Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus.Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder Management of obsessive-compulsive disorder comorbid with bipolar disorder.Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.Neurological perspectives on voltage-gated sodium channels.Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond.Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.Novel pharmacological agents targeting memory and cognition in the treatment of anxiety disorders.Co-occurrence of anxiety and bipolar disorders: clinical and therapeutic overview.Pharmacological treatment of obsessive-compulsive disorder Recent advances in the chemistry and biology of benzothiazoles.Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.

P2860

Q21203920-D30E12A0-F3DA-4FBF-8E36-94FC5F5EA3D6 Q24202239-0C9A9665-C4F7-4A1A-92F1-775A2F9092CB Q24242629-22434841-54B6-4704-A8D5-7339BBDFBBBF Q24629266-CC25BCEA-CF20-42B4-A816-A3553DEE32A4 Q24633004-7CCD666F-D59D-46AD-8717-FDDF76DBB768 Q26742196-5B14010F-9E72-42D8-9C19-B598E37DEDF6 Q26770756-725CE3E9-D6A7-459F-9C28-EA35754C1DC6 Q26851461-F8DC0322-929E-40EE-81A4-FE65EFB2EEB2 Q28075617-5BAF01A6-89E2-4A5B-BC35-DB775C2F6529 Q33721019-BB4E224F-2286-4705-8B70-CA3F02B7E90B Q34104378-26945CD2-1418-4513-959B-1E22644EF1DD Q34603059-CC953F67-115D-415E-ABFB-226A0C4FA18F Q35212987-C903150E-131A-414F-BB3F-C6675B44B4F6 Q35679478-CBA49A2B-4A62-42ED-A4A7-35007B60E385 Q35897264-24C1C54C-1F8C-4B15-A9B1-20717A8BD4F4 Q35944981-C0A65411-4A23-4ACD-B6AB-310B2455C093 Q35967025-9E65F5BD-56E7-4571-B31A-1B680AC8162A Q36029739-AC3BFB63-13C5-4FC7-A381-BBCC2705550F Q36323051-42534FDA-0435-4292-AB77-372F7E5964DF Q36374329-C3939431-E2F3-41B8-9A50-420F2B275CDD Q36434538-85362517-D31F-489B-A137-D4263F2A4201 Q36475830-87BE12FA-1925-427D-8040-FB4A65731995 Q36483649-DCD983FE-B768-409C-A617-377BAB1E7258 Q36906277-331198A9-78E9-4DB1-9A93-A53114C6F8CF Q36944201-9F3EA7CE-AD4D-4F62-9A1B-E98A510F6D8B Q37030195-4E6534E0-709B-4C2A-8AA2-4F92E3EF1F02 Q37235692-315384FF-2A9E-418E-8B3E-B3EA60DE9619 Q37335788-31B55C0D-819C-48F3-A5BD-5F768362EE40 Q37352930-49B792DC-9B52-4B4A-AF30-10B764B32B3C Q37400532-C3388A54-31A1-414C-8729-A9F5BF803EBF Q37442874-95BF9C89-0FAB-458C-B302-1D5C637B5325 Q38042001-A839C0D3-1173-473C-8716-FAE53DC59B7C Q38057736-C605058E-21AD-47D7-A623-303E28C800B8 Q38105535-00978480-902D-44AB-9793-9BF24F467845 Q38137924-C7585C25-C22F-4E95-A69D-A8D67A503704 Q38194541-67C0670B-8046-4D01-B2AE-97799AF34765 Q38242548-F884DE0A-A205-45DB-8F74-7F4D5E4E3AAA Q38355999-EC0EF3D0-B2FD-409D-98FB-1576363B8685 Q38787388-D6D864BE-A01F-4E71-96B1-616F55BE2C3C Q38954648-DD364551-B5BC-471D-9C95-7994489EBBA4

P2860

Riluzole in the treatment of mood and anxiety disorders.

http://www.wikidata.org/entity/Q37242602

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Riluzole in the treatment of mood and anxiety disorders.

@en

Riluzole in the treatment of mood and anxiety disorders.

@nl

type

label

Riluzole in the treatment of mood and anxiety disorders.

@en

Riluzole in the treatment of mood and anxiety disorders.

@nl

prefLabel

Riluzole in the treatment of mood and anxiety disorders.

@en

Riluzole in the treatment of mood and anxiety disorders.

@nl

P1433

Q37242602-AE6AE5F5-1109-46B5-8E49-FB319C3DAEEF

P1476

Q37242602-54811E20-82BA-4A66-ABA2-EB6574573709

P2093

Q37242602-56917F51-6212-404A-B5BB-53A4061EA232

Q37242602-5AF229D8-81C3-4642-8AC9-A168B4A77B8C

Q37242602-63A1B5FE-FC79-48E1-AAC8-85388A8110B0

Q37242602-64B24C36-BA92-466C-ACBF-60C8CE18D768

Q37242602-A3C9CB08-41AE-4C55-989A-BFC37D27CBAC

P2860

Q37242602-0033399C-129B-4011-940F-338F48B575CB

Q37242602-3DBB2C6B-7A36-4495-B967-C12A2E4D318E

Q37242602-5473650D-E497-48A2-BE5C-7B946BB1DDBC

Q37242602-60084C1F-FB8D-4C86-B26A-5C650936A9B6

Q37242602-8DAFA5D9-928D-4C81-8B6E-9E8C7786CC8B

Q37242602-9E1CA9E9-5399-4E80-931C-2B445178AED7

Q37242602-B447CCB7-D77E-489E-9D1A-2380B09C59E7

Q37242602-F076A0BA-7492-424F-A6E4-CC9F4382142D

Q37242602-F08FDDD8-885C-48A1-A891-96A2C913513B

Q37242602-F0ED722A-F9B4-4ACC-A98B-12A6797EAF6A

P2888

Q37242602-2B7199FC-ED6F-401F-A6F9-E431E3497BD8

P304

Q37242602-ED7685C7-75C8-450E-B1E0-1F5CADEB7B46

P31

Q37242602-11CB08FF-58B0-49E3-A0ED-0254279ACA5A

Q37242602-42c36022-d4f4-461c-8ba9-cdd326cb703c

P356

Q37242602-CEA18F98-4B9B-466B-97AC-AA9A9E13223A

P433

Q37242602-4EE39EB2-12C0-4D47-A0B6-18A32C16E89F

P478

Q37242602-C4122A8B-A806-4AD2-ABA8-663C6CFDFA24

P50

Q37242602-4DA91530-DD28-4C83-B977-BAF2207187A5

P577

Q37242602-4FB80A53-2F94-4440-AA73-F466ED4C1742

P5875

Q37242602-D5663AC9-A0BE-4381-A31B-ED4E1E441C25

P6179

Q37242602-28CA5B11-6E0E-45DA-A540-2F6E45076E2E

P698

Q37242602-E4B18A82-5EDA-4275-A3B1-4CFE83B96995

P356

00023210-200822090-00004

P1433

P1476

Riluzole in the treatment of mood and anxiety disorders.

@en

P2093

Gerard Sanacora

http://www.w3.org/2001/XMLSchema#string

John H Krystal

http://www.w3.org/2001/XMLSchema#string

Michael Bloch

http://www.w3.org/2001/XMLSchema#string

Mounira Banasr

http://www.w3.org/2001/XMLSchema#string

Vladimir Coric

http://www.w3.org/2001/XMLSchema#string

P2860

The assessment of anxiety states by rating

Beyond monoamines: glutamatergic function in mood disorders.

Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions.

The pharmacology and mechanism of action of riluzole.

Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action.

Intoxication with riluzole in Huntington's disease.

Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study.

Effect of MX-68 on airway inflammation and hyperresponsiveness in mice and guinea-pigs.

Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis.

Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.

P2888

00023210-200822090-00004

P304

761-786

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/00023210-200822090-00004

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Christopher Pittenger

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23166692

http://www.w3.org/2001/XMLSchema#string

P6179

1021915133

http://www.w3.org/2001/XMLSchema#string

P698

18698875

http://www.w3.org/2001/XMLSchema#string